Company: NDRA
Filing Date: 2025-07-09
Form Type: S-1
Source: 0001654954-25-007870
Chunk: 13

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-07-09
Form: S-1
Chunk 13
---
 of July 8, 2025 and excludes the following: |   |                                                                                                                                                                                                                            |
|                                                                                                                                                                                   | · | 180,707 shares of common stock issuable upon the exercise of outstanding warrants at a weighted-average exercise price of $85.38 per share;                                                                                |
|                                                                                                                                                                                   | · | 1 share of common stock issuable upon the conversion of outstanding shares of Series A Convertible Preferred Stock;                                                                                                        |
|                                                                                                                                                                                   | · | 266 shares of common stock issuable upon the exercise of outstanding stock options issued pursuant to our 2016 Omnibus Incentive Plan (the “Incentive Plan”) at a weighted average exercise price of $26,594.61 per share; |
|                                                                                                                                                                                   | · | 179,474 shares of common stock issuable upon the vesting of Restricted Stock Units issued pursuant to the Incentive Plan; and                                                                                              |
|                                                                                                                                                                                   | · | 309 shares of common stock reserved for future issuance under the Incentive Plan.                                                                                                                                          |

| 14 |

<div align='center'>RISK FACTORS</div>

Investing in our securities involves risks. Before you make a decision to buy our securities, in addition to the risks and uncertainties discussed above under “Cautionary Note Regarding Forward-Looking Statements,” you should read and consider carefully the following risk factors as well as the risk factors described under the section captioned “Risk Factors” contained in our Annual Report on Form 10-K for the year ended December 31, 2024, which is incorporated by reference in this prospectus, together with the other information contained in or incorporated by reference in this prospectus, including our consolidated financial statements and the related notes. Each of these risk factors, either alone or taken together, could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our common stock. There may be additional risks that we do not presently know of or that we currently believe are immaterial, which could also impair our business and financial position. If any of the events described below were to occur, our financial condition, our ability to access capital resources, our results of operations and/or our future growth prospects could be materially and adversely affected, and the market price of our common stock could decline. As a result, you could lose some or all of any investment you may make in our securities.

Risks Related to this Offering and Our Securities

We have a history of operating losses and will need to raise